Stockreport

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

Pyxis Oncology, Inc.  (PYXS) 
PDF -  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinom [Read more]